Abstract
The use of earlier beta-blockers (BB) has generally been considered contraindicated in individuals with reactive airways disease. This report described a meta-analysis of randomized, blinded, placebo-controlled trials of the recently available cardioselective BB in individuals with reactive airway diseases. On the basis of findings in 29 studies, the authors found that a single dose of cardioselective BB was followed by a small mean decrease in FEV1 (7.5%) without an increase in symptoms or need for inhaled albuterol use.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
